Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 7 Nov 2026
Promising but preliminary

Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia.

Using matched unrelated bone marrow donors for high-risk leukemia dramatically improves survival compared to mismatched donors, especially preventing treatment-related deaths.

Registry-based doubly-robust analysis of 1,963 AML patients receiving first allogeneic HSCT in Taiwan showed that matched unrelated donor transplantation was associated with superior overall survival over mismatched unrelated and haploidentical donors, driven by lower non-relapse mortality. The survival advantage of MUD was most pronounced in high/very-high-risk disease (42.7% vs 28.5% 3-year OS), supporting risk-adapted donor selection with MUD prioritization for high-risk AML.

What the study was

Study design
retrospective_registry_cohort
Category
hematologic_malignancies
Maturity
Validated
Journal
Transplantation and Cellular Therapy

Why it surfaced

Largest AML HSCT donor-selection registry study in Asian ATG-prevalent practice; risk-adapted MUD prioritization directly practice-changing for high-risk AML; doubly-robust causal analysis.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.